S&P DJI Announces September 2026 Quarterly Rebalance
Filed with ASX · · 6 pages · English
PYC Therapeutics Limited on 6ix
In the deck
Earlier from PYC Therapeutics
- Investor Webinar Presentation Q3 2026
- ADOA Program - Data Presentation
- Ceasing to be a substantial holder
- PKD - Presentation of Clinical Safety Data
- 2026 Corporate Governance Statement
Later from PYC Therapeutics
- PKD - First Patient Dosed in OLE Study
- RP11 program - presentation at Euretina 2026
- PKD Program - Presentation of Data at ASN Conference
- Notification of cessation of securities - PYC
- Application for quotation of securities - PYC
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics